Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Dellavolpe

Critical Care Medicine Fort Sam Houston, TX Medical Doctor

NPI 1720255599 CMS profile 1066984

3551 Roger Brooke Dr, McHe-Qd, Fort Sam Houston, TX 78234

Open in the dashboard

General payments

$39,828

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$426,480 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Jeffrey Dellavolpe of Fort Sam Houston, TX is reported in the CMS Open Payments database as having received $39,828 across 136 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $426,480 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,519 15
2024 General $11,003 24
2023 General $10,571 51
2022 General $10,843 24
2021 General $469 7
2020 General $243 2
2019 General $1,180 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Dellavolpe
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Jeffrey Dellavolpe were reported at $5,519. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Jeffrey Dellavolpe Critical Care Medicine median Middle half National median
2019 $1,180 $149 $51–$535 $163
2020 $243 $110 $30–$325 $114
2021 $469 $125 $34–$403 $132
2022 $10,843 $157 $49–$582 $149
2023 $10,571 $162 $56–$621 $160
2024 $11,003 $168 $53–$634 $164
2025 $5,519 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius USA Marketing, Inc. $13,148 20 payments
  2. NxStage Medical, Inc. $5,578 8 payments
  3. Medtronic, Inc. $5,543 11 payments
  4. Vantive US Healthcare LLC $4,931 8 payments
  5. Imbed Biosciences Inc. $2,031 23 payments
  6. ExThera Medical Corporation $1,704 4 payments
  7. Inari Medical, Inc. $1,504 11 payments
  8. Abbott Laboratories $1,147 12 payments
  9. Draeger Medical Systems, Inc $986 3 payments
  10. Abiomed $908 9 payments
  11. Other $2,348 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,186 111 payments
  2. Consulting Fee $9,100 4 payments
  3. Travel and Lodging $6,967 14 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,825 3 payments
  5. Education $3,949 2 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
  7. Honoraria $300 1 payment
Products named General payments · program years 2019–2025
  1. NOVALUNG SYSTEM $5,333 15 payments
  2. Renal - Acute $4,931 8 payments
  3. NXSTAGE SYSTEM ONE $4,395 5 payments
  4. MC3 NAUTILUS(TM) ECMO OXYGENATOR $3,713 4 payments
  5. MC3 Crescent Jugular Dual Lumen Catheter $1,699 5 payments
  6. CT THROMBECTOMY SYSTEM KIT $1,652 12 payments
  7. FLOWTRIEVER CATHETER, S $1,652 12 payments
  8. Impella $769 7 payments
  9. 2ND GEN CENTRIMAG PRIMARY CONSOLE $573 8 payments
  10. Nautilus $211 1 payment
  11. Other $2,194 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$130,752

Medicare's payments for the services billed

Medicare patients

274

Average age 73

Services billed

881

112 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Heart failure 65%
Atrial fibrillation 59%
Diabetes 58%
Chronic kidney disease 55%
Arthritis 45%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record